These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36413434)

  • 1. Public health perspective on prostate-specific antigen screening: Implications of overdiagnosis and differences in health insurance systems across countries.
    Takahashi T
    J Med Screen; 2023 Mar; 30(1):49-50. PubMed ID: 36413434
    [No Abstract]   [Full Text] [Related]  

  • 2. Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit.
    Vickers A; O'Brien F; Montorsi F; Galvin D; Bratt O; Carlsson S; Catto JW; Krilaviciute A; Philbin M; Albers P
    BMJ; 2023 May; 381():e071082. PubMed ID: 37197772
    [No Abstract]   [Full Text] [Related]  

  • 3. Two conflicting guidelines on prostate specific antigen screening in Japan.
    Takahashi T
    Jpn J Clin Oncol; 2023 Mar; 53(3):280-283. PubMed ID: 36533417
    [No Abstract]   [Full Text] [Related]  

  • 4. Modern prostate cancer diagnostics reduce overdiagnosis - will they open up for population-based screening?
    Bratt O; Lilja H
    Scand J Urol; 2021 Dec; 55(6):491-492. PubMed ID: 34605720
    [No Abstract]   [Full Text] [Related]  

  • 5. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
    Draisma G; Etzioni R; Tsodikov A; Mariotto A; Wever E; Gulati R; Feuer E; de Koning H
    J Natl Cancer Inst; 2009 Mar; 101(6):374-83. PubMed ID: 19276453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for clinically significant prostate cancer, overdiagnosis, active surveillance, and PSA screening.
    Takahashi T
    World J Urol; 2024 Mar; 42(1):167. PubMed ID: 38492072
    [No Abstract]   [Full Text] [Related]  

  • 7. Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis.
    Horton RH; Dunlop MG; Houlston RS; Lucassen A; McCartney M; McNeill A; Sud A
    Br J Cancer; 2023 Jan; 128(1):1-2. PubMed ID: 36443602
    [No Abstract]   [Full Text] [Related]  

  • 8. Response to: Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis (BJC-LT3342090).
    Green HD; Merriel SWD; Oram RA; Ruth KS; Tyrrell J; Jones SE; Thirlwell C; Weedon MN; Bailey SER
    Br J Cancer; 2023 Feb; 128(4):487-488. PubMed ID: 36536048
    [No Abstract]   [Full Text] [Related]  

  • 9. Polygenic risk scores and prostate cancer screening: a recipe for more overdiagnosis?
    Klein RJ
    BJU Int; 2022 Mar; 129(3):271. PubMed ID: 35297162
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostate-specific antigen screening for prostate cancer in countries with publicly funded health insurance.
    Takahashi T
    Public Health; 2023 Nov; 224():e2-e3. PubMed ID: 37258313
    [No Abstract]   [Full Text] [Related]  

  • 11. Screening for prostate cancer: an updated review.
    Marta GN; Hanna SA; Fernandes da Silva JL; Carvalho Hde A
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):101-8. PubMed ID: 23259431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 13. [Current aspects of prostate cancer screening].
    Jalón Monzón A; Escaf Barmadah S; Viña Alonso LM; Jalón Monzón M
    Semergen; 2017; 43(5):387-393. PubMed ID: 27562331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized Study of Screening for Prostate Cancer.
    Walter SD; Hu J; Talala K; Tammela T; Taari K; Auvinen A
    Cancer Causes Control; 2021 Nov; 32(11):1299-1313. PubMed ID: 34313874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.
    Vickers AJ; Sjoberg DD; Ulmert D; Vertosick E; Roobol MJ; Thompson I; Heijnsdijk EA; De Koning H; Atoria-Swartz C; Scardino PT; Lilja H
    BMC Med; 2014 Feb; 12():26. PubMed ID: 24512643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overdiagnosis and overtreatment of prostate cancer.
    Loeb S; Bjurlin MA; Nicholson J; Tammela TL; Penson DF; Carter HB; Carroll P; Etzioni R
    Eur Urol; 2014 Jun; 65(6):1046-55. PubMed ID: 24439788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis.
    Nyame YA; Gulati R; Heijnsdijk EAM; Tsodikov A; Mariotto AB; Gore JL; Etzioni R
    J Natl Cancer Inst; 2021 Oct; 113(10):1336-1342. PubMed ID: 33963850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.
    Morgan T; Palapattu G; Wei J
    Curr Urol Rep; 2015 Sep; 16(9):63. PubMed ID: 26169584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate Cancer Screening and the Associated Controversy.
    Tabayoyong W; Abouassaly R
    Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lifetime risk of prostate cancer overdiagnosis in Australia: quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach.
    Pathirana T; Hayen A; Doust J; Glasziou P; Bell K
    BMJ Open; 2019 Mar; 9(3):e022457. PubMed ID: 30858156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.